Shangya Technology (6130) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 上亞科技

Shangya Technology (6130) reported revenue of NT$17.8 million for Oct 2026, +55.4% year on year and +69.1% from the previous month. Revenue for Jan–Oct 2026 was NT$153.1 million (+18.7% year on year).

In Oct 2026, it ranked No. 128 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$11.9 million24/10Nov 2024 NT$16 millionDec 2024 NT$14.4 millionJan 2025 NT$7.7 millionFeb 2025 NT$21.1 million25/02Mar 2025 NT$10.8 millionApr 2025 NT$15.7 millionMay 2025 NT$12.6 millionJun 2025 NT$10.4 million25/06Jul 2025 NT$11.6 millionAug 2025 NT$13.2 millionSep 2025 NT$14.3 millionOct 2025 NT$11.5 million25/10Nov 2025 NT$12.2 millionDec 2025 NT$13.2 millionJan 2026 NT$17.1 millionFeb 2026 NT$8 million26/02Mar 2026 NT$14.3 millionApr 2026 NT$14.8 millionMay 2026 NT$17.1 millionJun 2026 NT$17.8 million26/06Jul 2026 NT$22.4 millionAug 2026 NT$13.4 millionSep 2026 NT$10.5 millionOct 2026 NT$17.8 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$17.8 million+55.4%+69.1%
Sep 2026NT$10.5 million-26.3%-21.6%
Aug 2026NT$13.4 million+1.4%-40.1%
Jul 2026NT$22.4 million+92.7%+26.0%
Jun 2026NT$17.8 million+70.9%+4.1%
May 2026NT$17.1 million+35.7%+15.7%
Apr 2026NT$14.8 million-6.0%+3.4%
Mar 2026NT$14.3 million+31.9%+79.0%
Feb 2026NT$8 million-62.2%-53.3%
Jan 2026NT$17.1 million+120.5%+29.2%
Dec 2025NT$13.2 million-8.2%+8.1%
Nov 2025NT$12.2 million-23.4%+6.7%
Oct 2025NT$11.5 million-3.6%-19.8%
Sep 2025NT$14.3 million-32.3%+7.9%
Aug 2025NT$13.2 million-11.6%+13.8%
Jul 2025NT$11.6 million-40.9%+11.8%
Jun 2025NT$10.4 million-51.9%-17.3%
May 2025NT$12.6 million-37.7%-19.9%
Apr 2025NT$15.7 million-15.1%+45.1%
Mar 2025NT$10.8 million-40.8%-48.7%
Feb 2025NT$21.1 million+324.4%+172.8%
Jan 2025NT$7.7 million-43.7%-46.2%
Dec 2024NT$14.4 million-25.7%-9.8%
Nov 2024NT$16 million-23.9%+34.3%
Oct 2024NT$11.9 million-8.7%-43.7%

Jan–Oct 2026 cumulative: NT$153.1 million (+18.7% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: Shangya Technology vs PEC / Shangya Technology vs Lotus Pharm / Shangya Technology vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

Company remark (original Chinese)

藥品收入及加工收入增加

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16